Your gateway to a free society
Article
'Still So Early On This Journey': Morgan Stanley Launches Lower-Cost Crypto Trading
'Still So Early On This Journey': Morgan Stanley Launches Lower-Cost Crypto Trading
Just a week after Amy Oldenburg, Morgan Stanley’s head of digital assets, spent the better part of an hour making a case for bitcoin that few clients have heard in full (a gap she says is the industry’s most urgent problem), the bank announces the launch of crypto trading on E*Trade, charging 50bps in a pilot that undercuts rivals like Coinbase, Robinhood, and Charles Schwab.
CoinDesk reports that Morgan Stanley’s Head of Wealth Management, Jed Finn, said the initiative goes beyond...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Mar 31, 2026 / Tyler Durden
Solar Stocks Surge As Energy Shock Revives Renewables Trade
Solar Stocks Surge As Energy Shock Revives Renewables Trade
Goldman analyst Adam Wijaya asked clients whether this year's surge in SolarEdge, Enphase Energy, and other solar stocks is reviving a familiar trade: higher crude oil and natural gas prices in Europe and globally, strengthening the case for renewables as the energy shock sparks a return to coal switching.
"Are we back to running the 2022 playbook?" Wijaya asked in a note published Monday.
Wijaya said, "Certainly seems that way based on recent px action in residential solar."
"SEDG is +79% YTD vs ENPH...
Read more
Feb 23, 2026 / Tyler Durden
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound).
Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug."
Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...
Read more
Feb 23, 2026 / Roman Kireev
The End of Artificial Employment
AI is not the killer—it is the coroner.
Read more
support
If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.
Support the liberty movement
Want to get in touch?